Holen Sie sich die Stockscreener-App
245.44
2.75%
6.57
Handel nachbörslich:
245.44
Schlusskurs vom Vortag:
$238.87
Offen:
$239.45
24-Stunden-Volumen:
1.17M
Relative Volume:
1.56
Marktkapitalisierung:
$31.66B
Einnahmen:
$2.09B
Nettoeinkommen (Verlust:
$-332.26M
KGV:
-59.29
EPS:
-4.14
Netto-Cashflow:
$16.06M
1W Leistung:
+0.00%
1M Leistung:
-1.35%
6M Leistung:
+55.93%
1J Leistung:
+37.08%
1-Tages-Spanne:
$235.93
$247.21
1-Wochen-Bereich:
$233.41
$249.58
52-Wochen-Spanne:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Sanctuary Advisors LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
City: Taking RNAi beyond the liver - BioCentury
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam - Yahoo Finance
4 Biotech Stocks Most Wall Street Analysts Are Bullish About - Yahoo Finance
Biotech CEO on RNAI and Medicine of the Future - Barron's
RNAi Technology Market to Witness Huge Growth by 2031 | Alnylam - openPR
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by StockNews.com to "Buy" Rating - MarketBeat
Alnylam Pharmaceuticals' SWOT analysis: strong data bolsters amvuttra stock outlook - Investing.com
Gene Therapy Market Key Players AnalysisNovartis Ag, Biogen - openPR
What Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) P/S Is Not Telling You - Simply Wall St
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Update - MarketBeat
Toronto Dominion Bank Acquires 3,315 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam's SWOT analysis: strong helios-b data bolsters amvuttra stock outlook - Investing.com India
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Boosted by Tidal Investments LLC - MarketBeat
Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells 1,752 Shares of Stock - MarketBeat
Geode Capital Management LLC Acquires 66,928 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Kovitz Investment Group Partners LLC Acquires New Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam's Onpattro Drug Uses Patented UTexas Tech, Suit Says (1) - Bloomberg Law
Where are the Opportunities in (ALNY) - Stock Traders Daily
Public Employees Retirement System of Ohio Sells 3,275 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Bleeding Disorders Treatment Market Emerging Trends and Growth - openPR
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Nomura Asset Management Co. Ltd. - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CAMP4 Therapeutics Taps Former Alnylam CEO, RNA Pioneer to Drive Next-Gen Gene Therapy Platform - StockTitan
Groupama Asset Managment Sells 2,849 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Benzinga
FAP therapy nucresiran safely reduces TTR in healthy people: Trial - FAP News Today
RNAi Therapeutics and Technology Market Top Players -Alnylam, - openPR
Two Sigma Advisers LP Sells 155,600 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
AL Amyloidosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Janssen Pharma, Prothena, Alexion Pharma, Alnylam Pharma, Attralus, Neurimmune AG - The Globe and Mail
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Polar Asset Management Partners Inc. - MarketBeat
Janus Henderson Group PLC Has $60.32 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Decreased by HighTower Advisors LLC - MarketBeat
Oligonucleotide Therapy Market Key Players AnalysisBPCI - openPR
Dyslipidemia Pipeline 2024: Clinical Trials Assessment, FDA - openPR
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Investment Management Corp of Ontario - MarketBeat
Royal London Asset Management Ltd. Has $76.94 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Small Interfering RNA (siRNA) Therapeutics Market Key Players - openPR
What Makes Alnylam (ALNY) a New Buy Stock - Yahoo Finance
Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Parkman Healthcare Partners LLC Invests $7.01 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp - MarketBeat
16,510 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Purchased by Erste Asset Management GmbH - MarketBeat
Bridgewater Associates LP Acquires New Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Why Is Alnylam Pharmaceuticals, Inc. (ALNY) Among the Best High Growth Healthcare Stocks to Invest In Now? - Yahoo Finance
PDT Partners LLC Decreases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Bellevue Group AG Sells 110,739 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
Eventide Asset Management LLC Buys 137,333 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals (FRA:DUL) EBIT : €-170 Mil (TTM As of Sep. 2024) - GuruFocus.com
Cerity Partners LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.56%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):